{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Participants who are alive following enrollment and study treatment.","groups":[{"description":"Avelumab 800 mg IV every two weeks in combination with radiation therapy\n\nAvelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle\n\nExternal beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy","id":"OG000","title":"1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Enrollment through end of study, an average of 11 months","title":"Percentage of Participants With Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}